0 Комментарии
0 Поделились
17 Просмотры
0 предпросмотр
Поиск
Знакомьтесь и заводите новых друзей
-
Войдите, чтобы отмечать, делиться и комментировать!
-
Precision Biologics: How Monoclonal Antibody Therapeutics Are Targeting Iron MetabolismThe Hemojuvelin Monoclonal Antibody Market is experiencing significant growth as monoclonal antibody therapeutics continue to target iron metabolism and related disorders. According to market reports, the global Hemojuvelin Monoclonal Antibody Market was valued at USD 400 million in 2024 and is projected to reach USD 1,500 million by 2035, exhibiting an impressive CAGR of 13.4% during...0 Комментарии 0 Поделились 96 Просмотры 0 предпросмотр
-
The Myeloperoxidase Monoclonal Antibody Market: Advancing Diagnostics and Therapeutics for Inflammatory DiseasesThe myeloperoxidase (MPO) monoclonal antibody market is a rapidly expanding niche within the broader biopharmaceutical landscape, offering powerful tools for the diagnosis, research, and treatment of a range of inflammatory and malignant diseases. The myeloperoxidase monoclonal antibody market is experiencing explosive growth, driven by the rising prevalence of chronic inflammatory...0 Комментарии 0 Поделились 2 Просмотры 0 предпросмотр
-
North America Hyperimmune Globulin Market Trends and Forecast 2031The hyperimmune globulin market is experiencing strong growth due to the rising demand for plasma-derived therapies and increasing awareness regarding immunological treatment solutions. Hyperimmune globulins are highly concentrated antibody products derived from human plasma and are widely used for infection prevention, post-exposure prophylaxis, and immune deficiency treatment. The growing...0 Комментарии 0 Поделились 383 Просмотры 0 предпросмотр
-
United States ADC for Solid Tumors Market Growing at 8.9% CAGR Through 2034The United States Antibody‑Drug Conjugate (ADC) for Solid Tumors market size was valued at approximately USD 0.55 billion in 2025. The market is projected to grow from approximately USD 0.58 billion in 2026 to around USD 1.04 billion by 2034, exhibiting a CAGR of about 8.9% during the forecast period. Antibody‑Drug Conjugates are targeted therapeutics that combine a monoclonal antibody that...0 Комментарии 0 Поделились 432 Просмотры 0 предпросмотр